Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
AssigneeMeyer Pharmaceuticals LLC
InventorJohn C. Hiserodt
Life of this patent
Estimating the term…
Abstract
This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.
Claims13
An improvement in the method of treating a human patient having a tumor by implanting at or around the site of a solid tumor in the patient a cell population comprising alloactivated lymphocytes that are allogeneic to the patient;
- wherein the implanting of the alloactivated lymphocytes in the patient generating a therapeutic response against tumor growth;
- the improvement comprising implanting at or around the site of a solid tumor in the patient a second cell population containing alloactivated lymphocytes that are allogeneic to the patient between 1 and 8 weeks after the implanting of the first cell population.
Dependencies are inferred from the claim text.